Patents by Inventor Roberto Pellicciari

Roberto Pellicciari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR PREPARATION OF BILE ACIDS AND DERIVATIVES THEREOF
    Publication number: 20190010184
    Abstract: The present application relates to a method of preparing compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, R1 is H, ?-OH, ?-OH, or an oxo group.
    Type: Application
    Filed: July 22, 2016
    Publication date: January 10, 2019
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • 3-DESOXY DERIVATIVE AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20190002493
    Abstract: The present application provides Compound 1: or a pharmaceutically acceptable salt or amino acid conjugate thereof. The present invention relates to an FXR activator and to methods of making and using said compound.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 3, 2019
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • METHODS AND INTERMEDIATES FOR THE PREPARATION OF BILE ACID DERIVATIVES
    Publication number: 20180371009
    Abstract: The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I or pharmaceutically acceptable salt, hydrate, solvate or amino acid, sulfate or glucuronide conjugate, or prodrug thereof.
    Type: Application
    Filed: June 22, 2018
    Publication date: December 27, 2018
    Inventors: Roberto Pellicciari, Antimo Gioiello, Gabriel Galvin, Ronald D Lewis, Mathew Yanik, Myoung Goo Kim, Fred Leusink, Bartjan Koning, Thomas Hensel
  • INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
    Publication number: 20180134667
    Abstract: The present disclosure discloses compounds capable of modulating the activity of ?-amino-?-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Application
    Filed: October 13, 2017
    Publication date: May 17, 2018
    Inventor: Roberto Pellicciari
  • PROCESS FOR PREPARING BILE ACID DERIVATIVES
    Publication number: 20180079776
    Abstract: The present invention relates to processes for preparing compounds of formula I: or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: August 21, 2017
    Publication date: March 22, 2018
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • TGR5 Modulators and Methods of Use Thereof
    Publication number: 20180016295
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Application
    Filed: April 7, 2017
    Publication date: January 18, 2018
    Inventor: Roberto Pellicciari
  • INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
    Publication number: 20170362185
    Abstract: The present disclosure discloses compounds capable of modulating the activity of ?-amino-?-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Application
    Filed: June 2, 2017
    Publication date: December 21, 2017
    Inventors: Roberto Pellicciari, Johan Auwerx, Nadia Raffaelli
  • Steroids as Agonists for FXR
    Publication number: 20170305961
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Application
    Filed: July 10, 2017
    Publication date: October 26, 2017
    Inventor: Roberto Pellicciari
  • Process for preparing bile acid derivatives
    Patent number: 9777038
    Abstract: The present invention relates to processes for preparing compounds of formula I: or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: October 3, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
    Patent number: 9763964
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: September 19, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • 3-DESOXY DERIVATIVE AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20170260225
    Abstract: The present application provides Compound 1: or a pharmaceutically acceptable salt or amino acid conjugate thereof. The present invention relates to an FXR activator and to methods of making and using said compound.
    Type: Application
    Filed: March 7, 2017
    Publication date: September 14, 2017
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • Steroids as agonists for FXR
    Patent number: 9732117
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: August 15, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • FARNESOID X RECEPTOR MODULATORS
    Publication number: 20170216316
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 3, 2017
    Inventor: Roberto Pellicciari
  • Inhibitors of ?-amino-?-carboxymuconic acid semialdehyde decarboxylase
    Patent number: 9708272
    Abstract: The present disclosure discloses compounds capable of modulating the activity of ?-amino-?-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: July 18, 2017
    Assignee: TES Pharma S.r.l.
    Inventors: Roberto Pellicciari, Johan Auwerx, Nadia Raffaelli
  • TREATMENT OF FIBROSIS USING FXR LIGANDS
    Publication number: 20170165277
    Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
    Type: Application
    Filed: October 21, 2016
    Publication date: June 15, 2017
    Inventors: Stefano Fiorucci, Roberto Pellicciari, Mark Pruzanski
  • TGR5 modulators and methods of use thereof
    Patent number: 9650409
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: May 16, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • FARNESOID X RECEPTOR MODULATORS
    Publication number: 20170101434
    Abstract: The present application provides a compound of formula I: or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1-R10, m, n, p, and are as described herein. The present invention relates generally to FXR modulators and to methods of making and using said compounds.
    Type: Application
    Filed: October 7, 2016
    Publication date: April 13, 2017
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • Farnesoid X receptor modulators
    Patent number: 9611289
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: April 4, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • TGR5 modulators and methods of use thereof
    Patent number: 9540414
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, or hydrate thereof. The compounds of formula A are TGR5 modulators useful for the treatment of disease.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: January 10, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Treatment of fibrosis using FXR ligands
    Patent number: 9498484
    Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: November 22, 2016
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Stefano Fiorucci, Roberto Pellicciari, Mark Pruzanski